brexucabtagene autoleucel (Tecartus, Zynteglo)
Jump to navigation
Jump to search
Indications
- treatment of adults with relapsed/refractory mantle cell lymphoma
- relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Dosage
- suspension of CAR-positive viable T-cells for infusion
* 20,000,000 CELLS/ML Injection
Adverse effects
- fever, cytokine release syndrome, hypotension, encephalopathy, fatigue, tachycardia, arrhythmia, infections, chills,hypoxia, cough, tremor, musculoskeletal pain, headache, nausea/vomiting, edema, motor dysfunction, constipation, diarrhea, anorexia, dyspnea, rash, insomnia, pleural effusion, aphasia
* Warnings
- hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
- hypersensitivity
- prolonged cytopenias
- hypogammaglobulinemia
- secondary malignancies
- Effects on Ability to Drive and Use Machines
- drug adverse effects of immunosuppressive agents
- drug adverse effects of biologic immunosuppressive agents
Mechanism of action
- CD19-directed genetically modified autologous car T-cell immunotherapy
More general terms
References
- ↑ FDA Cellular and Gene Therapy Products. Aug 14, 2020 TECARTUS (brexucabtagene autoleucel) https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel
- ↑ FDA July 27, 2020 FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
- ↑ WikipediaL Brexucabtagene autoleucel https://en.wikipedia.org/wiki/Brexucabtagene_autoleucel